Inverse agonism and its therapeutic significance
Open Access
- 1 January 2011
- journal article
- educational forum
- Published by Medknow in Indian Journal of Pharmacology
- Vol. 43 (5) , 492-501
Abstract
A large number of G-protein-coupled receptors (GPCRs) show varying degrees of basal or constitutive activity. This constitutive activity is usually minimal in natural receptors but is markedly observed in wild type and mutated (naturally or induced) receptors. According to conventional two-state drug receptor interaction model, binding of a ligand may initiate activity (agonist with varying degrees of positive intrinsic activity) or prevent the effect of an agonist (antagonist with zero intrinsic activity). Inverse agonists bind with the constitutively active receptors, stabilize them, and thus reduce the activity (negative intrinsic activity). Receptors of many classes (α-and β-adrenergic, histaminergic, GABAergic, serotoninergic, opiate, and angiotensin receptors) have shown basal activity in suitable in vitro models. Several drugs that have been conventionally classified as antagonists (β-blockers, antihistaminics) have shown inverse agonist effects on corresponding constitutively active receptors. Nearly all H 1 and H 2 antihistaminics (antagonists) have been shown to be inverse agonists. Among the β-blockers, carvedilol and bucindolol demonstrate low level of inverse agonism as compared to propranolol and nadolol. Several antipsychotic drugs (D 2 receptors antagonist), antihypertensive (AT 1 receptor antagonists), antiserotoninergic drugs and opioid antagonists have significant inverse agonistic activity that contributes partly or wholly to their therapeutic value. Inverse agonism may also help explain the underlying mechanism of beneficial effects of carvedilol in congestive failure, naloxone-induced withdrawal syndrome in opioid dependence, clozapine in psychosis, and candesartan in cardiac hypertrophy. Understanding inverse agonisms has paved a way for newer drug development. It is now possible to develop agents, which have only desired therapeutic value and are devoid of unwanted adverse effect. Pimavanserin (ACP-103), a highly selective 5-HT 2A inverse agonist, attenuates psychosis in patients with Parkinson's disease with psychosis and is devoid of extrapyramidal side effects. This dissociation is also evident from the development of anxioselective benzodiazepines devoid of habit-forming potential. Hemopressin is a peptide ligand that acts as an antagonist as well as inverse agonist. This agent acts as an antinociceptive agent in different in vivo models of pain. Treatment of obesity by drugs having inverse agonist activity at CB 1/2 receptors is also underway. An exciting development is evaluation of β-blockers in chronic bronchial asthma-a condition akin to congestive heart failure where β-blockade has become the standard mode of therapy. Synthesis and evaluation of selective agents is underway. Therefore, inverse agonism is an important aspect of drug-receptor interaction and has immense untapped therapeutic potential.Keywords
This publication has 65 references indexed in Scilit:
- Pimavanserin, a Serotonin2A Receptor Inverse Agonist, for the Treatment of Parkinson's Disease PsychosisNeuropsychopharmacology, 2009
- α2‐Adrenoceptor action on cell proliferation and mammary tumour growth in miceBritish Journal of Pharmacology, 2008
- Chronic Exposure to Beta-Blockers Attenuates Inflammation and Mucin Content in a Murine Asthma ModelAmerican Journal of Respiratory Cell and Molecular Biology, 2008
- Biology and therapeutic potential of cannabinoid CB2receptor inverse agonistsBritish Journal of Pharmacology, 2008
- Hemopressin is an inverse agonist of CB 1 cannabinoid receptorsProceedings of the National Academy of Sciences, 2007
- Mepyramine, a Histamine H1 Receptor Inverse Agonist, Binds Preferentially to a G Protein-coupled Form of the Receptor and Sequesters G ProteinJournal of Biological Chemistry, 2004
- CarvedilolDrugs, 2003
- Antipsychotics with inverse agonist activity at the dopamine D3 receptorJournal of Neural Transmission, 1996
- Further evidence that naloxone acts as an inverse opiate agonist: Implications for drug dependence and withdrawaLLife Sciences, 1996
- Accelerated communciation: Constitutive μ opioid receptor activation as a regulatory mechanism underlying narcotic tolerance and dependenceLife Sciences, 1994